uploads///Part_Graph

Madrigal Pharmaceuticals Stock in the First Half of October

By

Oct. 19 2018, Published 1:25 p.m. ET

Madrigal Pharmaceuticals’ stock price movement

On October 15, Madrigal Pharmaceuticals (MDGL) closed at $189.18, which was 1.28% lower than its previous closing price on October 12. On October 15, the company had a market capitalization of $2.91 billion.

Madrigal Pharmaceuticals stock price had a solid run in the first week of June. At that time, it had released positive data from the Phase 2 trial at the end of 36 weeks for the investigational thyroid hormone receptor-β (or THR) agonist, MGL-3196, in the NASH indication on May 31.

Article continues below advertisement

However, Madrigal Pharmaceuticals’ (MDGL) stock price has dropped 10.87% from $212.26 on October 1 to $189.18 on October 15. Investors have been concerned about the company’s growth prospects and its MGL-3196 research program after its competitor Viking Therapeutics (VKTX) released strong top-line data for its investigational VK2809 drug in the nonalcoholic fatty liver disease (or NAFLD) indication.

Madrigal Pharmaceuticals is currently trading 387.33% higher than its 52-week-low price of $38.82 and 41.97% lower than its 52-week-high price of $325.98. 

Based on its closing price on October 15, the company has returned -4.95%, -16.35%, and -34.15%, respectively, in the last week, the last month, and the last quarter. Madrigal Pharmaceuticals has returned 60.93%, 274.1%, and 106.1%, respectively, in the last half year, the last year, and year-to-date.

Analysts’ recommendations and target price for Madrigal Pharmaceuticals

The 12-month consensus analyst recommendation for Madrigal Pharmaceuticals on October 16 was for a “buy.” The 12-month consensus target price for the company is $322.86, which is 70.66% higher than its last closing price on October 15. The highest target price estimate for the company is $392.00, and its lowest target price estimate is $300.00.

Of the nine analysts covering Madrigal Pharmaceuticals in the first half of October, the majority of analysts gave positive recommendations for the stock. Two analysts rated the company as a “strong buy,” and four rated the company as a “buy.” Three analysts rated the company as a “hold.”

At the end of the second quarter, the company had $490.31 million in cash on its balance sheet. The company doesn’t carry any debt on its balance sheet.

In the next article, we’ll discuss Madrigal Pharmaceuticals’ NASH program.

Advertisement

More From Market Realist

  • CONNECT with Market Realist
  • Link to Facebook
  • Link to Twitter
  • Link to Instagram
  • Link to Email Subscribe
Market Realist Logo
Do Not Sell My Personal Information

© Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.